LISTING OF CLAIMS

1-65 (canceled)

66.(new) A compound of formula (I):



(I)

wherein

R_a and R_b together with the nitrogen to which they are attached form a 6 membered heterocycle optionally including up to 3 additional heteroatoms;

n is 0-4;

R_1 is hydrogen or halo;

one of R_2 and R_3 is G and the other is hydrogen or halo;

G is



(ii)

L_3 is phenyl or naphthyl;

L_6 is C_{1-5} alkylene;

L_7 is C_{1-5} alkylene or absent;

R_7 is H, hydroxyl, halo, or C_{2-6}alkoxy or is absent where the carbon linking L_6 and L_7 participates in a double bond;

R_{10} is H, C_{1-8}alkyl, C_{3-8}alkenyl, C_{3-7}cycloalkyl, (C_{3-7}cycloalkyl)C_{1-6}alkylene, (C_{2-15}heterocyclyl)C_{1-6}alkylene, or (phenyl)C_{1-6}alkylene;

wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be unsubstituted or substituted with between 1 and 3 substituents independently selected from halo, amino, nitro, hydroxyl, and C_{1-3} alkyl;

or a pharmaceutically acceptable salt, ester, or amide thereof.

67. (new) A compound of claim 66, wherein NR_aR_b taken together form piperidyl or methylpiperidyl.

68. (new) A compound of claim 67, wherein NR_aR_b taken together form piperidyl.

69. (new) A compound of claim 66, wherein R_2 is G.

70. (new) A compound of claim 66, wherein R_3 is G.

71. (new) A compound of claim 66, wherein n is between 1 and 4, inclusive.

72. (new) A compound of claim 71, wherein n is 1.

73. (new) A compound of claim 66, wherein L_3 is phenylene.

74. (new) The compound 1-{3-[2'-(1-Isopropyl-piperidin-4-yl)-biphenyl-4-yloxy]-propyl}-piperidine.

75. (new) A pharmaceutical composition comprising a compound of claim 66 or 74 and a pharmaceutically acceptable excipient.

76. (new) A compound of claim 66 or 74, isotopically-labelled to be detectable by positron emission tomography or single-photon emission computed tomography.

77. (new) A method of inhibiting histamine H_3 receptor activity in a subject, comprising administering an effective amount of a compound of claim 66 or 74 to a subject in need of such inhibition of histamine H_3 receptor activity.

78. (new) A method of treating a subject having a disease or condition modulated by histamine H_3 receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of claim 66 or 74.

79. (new) A method of claim 78, wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

80. (new) A method for treating a disease or condition modulated by at least one receptor selected from the histamine H_1 receptor and the histamine H_3 receptor, said method comprising

(a) administering to a subject in need thereof a jointly effective amount of a histamine H_1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 66 or 74, said method providing a jointly therapeutically effective amount of said compounds.

81. (new) The method of claim 80 wherein the histamine H_1 receptor antagonist and the compound of claim 66 are present in the same dosage form.

82. (new) The method of claim 80 wherein the histamine H_1 receptor antagonist and the compound of claim 74 are present in the same dosage form.

83. (new) A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H_2 receptor and the histamine H_3 receptor in a subject, comprising (a) administering to the subject in need thereof a jointly effective amount of a histamine H_2 receptor antagonist compound, and (b) administering to said subject a jointly effective amount of a compound of claim 66 or 74, said method providing a jointly therapeutically effective amount of said compounds.

84. (new) The method of claim 83 wherein the histamine H_2 receptor antagonist and the compound of claim 66 are present in the same dosage form.

85. (new) The method of claim 83 wherein the histamine H_2 receptor antagonist and the compound of claim 74 are present in the same dosage form.

86. (new) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 66 or 74.

87. (new) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 66 or 74.

88. (new) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 66 or 74.

89. (new) A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 66 or 74.

90. (new) A method for studying disorders mediated by the histamine H_3 receptor, comprising using an ^{18}F-labeled compound of claim 66 as a positron emission tomography (PET) molecular probe.